Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols

Abstract

A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is similarly provided. The administration of a composition containing an effective dose of at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol for the treatment of obesity is likewise provided.

What is claimed is:  
     
         1 . A method of treating obesity in a subject in need thereof comprising: 
 identifying a subject presenting with obesity;    administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in combination with a pharmaceutically effective dose of at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.    
     
     
         2 . The method of  claim 1 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         3 . The method of  claim 1 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         4 . The method of  claim 1 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols.  
     
     
         5 . The method of  claim 1 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         6 . The method of  claim 5 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         7 . The method of  claim 1 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         8 . The method of  claim 1 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         9 . The method of  claim 7 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         10 . The method of  claim 7 , wherein said mucolytic is guaifenesin.  
     
     
         11 . A method of reducing body fat comprising administering to a subject in need of body fat reduction a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with a pharmaceutically effective dose of at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.  
     
     
         12 . The method of  claim 11 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         13 . The method of  claim 11 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         14 . The method of  claim 11 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, docosapentaenoic alcohol, and all other diunsaturated and polyunsaturated fatty alcohols.  
     
     
         15 . The method of  claim 11 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         16 . The method of  claim 15 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         17 . The method of  claim 11 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         18 . The method of  claim 17 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         19 . The method of  claim 17 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         20 . The method of  claim 17 , wherein said mucolytic is guaifenesin.  
     
     
         21 . A method of improving insulin sensitivity in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.  
     
     
         22 . The method of  claim 21 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         23 . The method of  claim 21 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         24 . The method of  claim 21 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.  
     
     
         25 . The method of  claim 21 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         26 . The method of  claim 25 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         27 . The method of  claim 21 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         28 . The method of  claim 27 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         29 . The method of  claim 27 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         30 . The method of  claim 27 , wherein said mucolytic is guaifenesin.  
     
     
         31 . A method of reducing hyperglycemia in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.  
     
     
         32 . The method of  claim 31 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         33 . The method of  claim 31 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         34 . The method of  claim 31 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.  
     
     
         35 . The method of  claim 31 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         36 . The method of  claim 35 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         37 . The method of  claim 31 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         38 . The method of  claim 37 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         39 . The method of  claim 37 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         40 . The method of  claim 37 , wherein said mucolytic is guaifenesin.  
     
     
         41 . A method of reducing hypercholesterolemia in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.  
     
     
         42 . The method of  claim 41 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         43 . The method of  claim 41 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         44 . The method of  claim 41 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.  
     
     
         45 . The method of  claim 41 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         46 . The method of  claim 45 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         47 . The method of  claim 41 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         48 . The method of  claim 47 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         49 . The method of  claim 47 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         50 . The method of  claim 47 , wherein said mucolytic is guaifenesin.  
     
     
         51 . A method of promoting weight loss in a subject in need thereof comprising administering to said subject a pharmaceutically effective dose of a conjugated fatty acid or conjugated fatty alcohol in conjunction with at least one chromium complex selected from the group consisting of chromium picolinate, chromium nicotinate, chromic tripicolinate, chromic polynicotinate, chromium chloride, chromium histidinate, and chromium yeasts.  
     
     
         52 . The method of  claim 51 , wherein said conjugated fatty acid is selected from the group consisting of a conjugated version of linoleic acid, linolenic acid, gamma linolenic acid, arachidonic acid, mead acid, stearidonic acid, alpha-eleostearic acid, eleostearic acid, pinolenic acid, docosadienic acid, docosatetraenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid.  
     
     
         53 . The method of  claim 51 , wherein said conjugated fatty acid is conjugated linoleic acid.  
     
     
         54 . The method of  claim 51 , wherein said conjugated fatty alcohol is selected from the group consisting of a conjugated version of linoleic alcohol, linolenic alcohol, gamma linolenic alcohol, arachidonic alcohol, mead alcohol, stearidonic alcohol, alpha-eleostearic alcohol, eleostearic alcohol, pinolenic alcohol, docosadienic alcohol, docosatetraenoic alcohol, octadecadienoic alcohol, octadecatrienoic alcohol, eicosatetraenoic alcohol, eicosapentaenoic alcohol, docosahexaenoic alcohol, and docosapentaenoic alcohol.  
     
     
         55 . The method of  claim 51 , wherein said composition further comprises at least one uncomplexed chelating agent.  
     
     
         56 . The method of  claim 55 , wherein said chelating agent is picolinic acid, nicotinic acid, or both.  
     
     
         57 . The method of  claim 51 , wherein said composition further comprises at least one of a cyclooxygenase inhibitor, a mucolytic, and a salicin-containing herb.  
     
     
         58 . The method of  claim 57 , wherein said at least one cyclooxygenase inhibitor is selected from the group consisting of indomethacin, ibuprofen, acetaminophen, and naproxen.  
     
     
         59 . The method of  claim 57 , wherein said salicin-containing herb is selected from the group consisting of  Boswellia serrata  (frankincense),  Betula lenta  (sweet birch),  Betula pubescens  (white birch),  Filipendula ulmaria  (meadowsweet),  Gautheria procumbens  (wintergreens),  Polulus balsamifera, Populus jackii  (balm of Gilead) and  Salix alba  (white willow).  
     
     
         60 . The method of  claim 57 , wherein said mucolytic is guaifenesin.